Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. leukemic-tes

LEUKEMIC-TEs

Unveiling the signature of transposable elements-derived transcripts – the transposcriptome – as a biomarker in human acute myeloid leukemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 LEUKEMIC-TEs project word cloud

Explore the words cloud of the LEUKEMIC-TEs project. It provides you a very rough idea of what is the project "LEUKEMIC-TEs" about.

adults    science    soft    accomplishment    relapsed    hematopoietic    background    genome    cancer    epigenetics    aberrant    gene    leukemias    fractions    pipelines    malignant    outcome    create    reprogramming    precursors    proper    oncoproteins    te    invaluable    transcriptome    industry    normal    complementary    thirds    patients    skills    largely    cd34cd38    progenitors    tool    leukemia    roles    frequent    homology    acute    categorization    explained    analytical    cell    therapies    decisive    difficult    unexplored    denser    subclassification    biomarkers    stem    throughput    tes    advent    regulation    demonstrated    scientific    tumorigenesis    solely    coverage    treat    chromosomes    lsc    tumorigenic    aml    basis    limited    technologies    ideal    signature    achievement    academy    samples    existence    transposable    expression    mediocre    networks    human    characterization    myeloid    collaborations    cells    pluripotency    bridge    excellence    directed    identification    thought    linked    sequencing    researcher    exclusive    provides    immunotherapeutically    lack   

Project "LEUKEMIC-TEs" data sheet

The following table provides information about the project.

Coordinator		 ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Project website https://tronolab.epfl.ch
 Total cost 175˙419 €
 EC max contribution 175˙419 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-04-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 175˙419.00

Map

 Project objective

Acute myeloid leukemia (AML) is the most common of the acute leukemias among adults. Relapsed AML patients are frequent but difficult to treat since effective therapies are limited. This mediocre outcome can be partially explained by the presence of leukemia stem cells (LSC) that maintain an aberrant hematopoietic process. LSC in AML were traditionally thought to be solely CD34CD38- cells. However, recent studies demonstrated the presence of LSC in cell fractions thought to be non-tumorigenic. Finding an LSC-specific signature would be decisive for a better categorization of patients and LSC exclusive targeting. This project considers the signature of transposable elements (TEs) as an ideal tool for the identification of LSC. TEs, with important roles in gene regulation, are linked to the reprogramming process to pluripotency and they are associated with tumorigenesis. Since they contribute up to two thirds of the human genome, TEs expression provides much denser coverage of chromosomes than gene-derived transcriptome. TEs signature in cancer has so far been largely unexplored per lack of proper technologies. The advent of high-throughput sequencing and the development of TE-directed analytical pipelines allow now the accomplishment of this project. The present proposal includes a comprehensive characterization of TEs transcriptome in normal and malignant hematopoietic precursors. An expected result is the achievement of a better subclassification of AML samples on the basis of their TEs expression homology to normal progenitors. The project will investigate the existence of TE-derived oncoproteins exclusive for LSC that could be immunotherapeutically targeted. This proposal has impact on the excellence of European science since it will create new collaborations and networks to find AML biomarkers. It would bridge academy with industry and will bring invaluable complementary scientific and soft skills to a researcher with an ideal background in cancer epigenetics.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEUKEMIC-TES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEUKEMIC-TES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

MY MITOCOMPLEX (2021)

Functional relevance of mitochondrial supercomplex assembly in myeloid cells

Read More  

CODer (2020)

The molecular basis and genetic control of local gene co-expression and its impact in human disease

Read More